azithromycin - for COVID-19 method

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA
deaths 0.56 [0.26, 1.21]< 10%1 study (- / 1)93.0 %seriousnot evaluable lowcrucial-
deaths (time to event analysis only) 0.56 [0.26, 1.21]< 10%1 study (- / 1)93.0 %seriousnot evaluable lowcrucial-
cardiac arrest 0.64 [0.27, 1.54]< 10%1 study (- / 1)84.0 %seriousnot evaluable lowimportant-
abnormal ECG findings 0.95 [0.47, 1.93]< 10%1 study (- / 1)55.6 %seriousnot evaluable lownon important-
arrhythmia 1.05 [0.57, 1.94]< 10%1 study (- / 1)43.4 %seriousnot evaluable lownon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 1 pathologies: 87,95,94,90,91,97 95